MedTrace Logo

The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy

NCT02910297 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine if cannabidiol (CBD) obtained via the state of Minnesota reduces seizures in patients with severe intractable epilepsy (Dravet Syndrome or Lennox Gastaut Syndrome), and to measure blood levels of CBD to help determine CBD concentration-response characteristics.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Samuel A Roiko, Ph.D. · Gillette Children's Specialty Healthcare

Eligibility

Min Age
2 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910297 on ClinicalTrials.gov